Healthcare tech company GoodRx (NASDAQ: GDRX) will be announcing earnings results this Wednesday afternoon. Here’s what to look for.

GoodRx beat analysts’ revenue expectations last quarter, reporting revenues of $194.8 million, down 1.9% year on year. It was a softer quarter for the company, with full-year revenue and EBITDA guidance missing analysts’ expectations significantly. It lost 100,000 customers and ended up with a total of 5.3 million.

Is GoodRx a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.

This quarter, the market is expecting GoodRx’s revenue to decline 9% year on year, a reversal from the 2.6% increase it recorded in the same quarter last year.

The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. GoodRx has missed Wall Street’s revenue estimates multiple times over the last two years.

Looking at GoodRx’s peers in the healthcare technology segment, only Omnicell has reported results so far. It exceeded analysts’ revenue estimates, delivering year-on-year sales growth of 14.9%. The stock traded up 14.5% on the results.

There has been positive sentiment among investors in the healthcare technology segment, with share prices up 5.7% on average over the last month. GoodRx is up 20.6% during the same time and is heading into earnings with an average analyst price target of $2.82 (compared to the current share price of $2.50).

ONE MORE THING: The $21 AI Application Stock Wall Street Forgot. While Wall Street obsesses over who’s building AI, one company is already using it to print money. And nobody’s paying attention.

AI chip stocks trade at ridiculous valuations. This company processes a trillion consumer signals monthly using AI and trades at a third of the price. The gap won’t last. The institutions will figure it out. You need to see this first. Read the FREE Report Before They Notice.